Stocktoria
Relay Therapeutics, Inc. RLAY
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-16
Relay Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $15.4M | $10.0M | $25.5M | $1.4M | $3.0M | $82.7M | — |
| R&D expense | — | — | — | — | — | $99.9M | $70.3M |
| Operating income | -$302.7M | -$372.5M | -$373.0M | -$299.3M | -$364.7M | -$55.8M | -$84.0M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$276.5M | -$337.7M | -$342.0M | -$290.5M | -$363.9M | -$52.4M | -$75.3M |
| EPS (diluted) | $-1.61 | $-2.36 | $-2.79 | $-2.59 | $-3.82 | $-5.40 | — |
| Operating cash flow | -$235.5M | -$249.1M | -$300.3M | -$229.5M | -$74.4M | -$102.5M | -$66.1M |
| Free cash flow | -$235.9M | -$251.1M | -$304.4M | -$238.6M | -$77.9M | -$104.4M | -$74.1M |
| Cash & equivalents | $84.0M | $124.3M | $143.7M | $151.8M | $280.1M | $447.6M | $42.0M |
| Total assets | $621.3M | $871.3M | $844.0M | $1.1B | $1.0B | $799.8M | $393.1M |
| Total liabilities | $54.3M | $93.5M | $92.0M | $149.6M | $110.6M | $36.5M | $35.7M |
| Shareholders' equity | $567.1M | $777.8M | $752.0M | $950.2M | $897.8M | $763.3M | -$180.4M |
Growth · year-over-year · Revenue CAGR -28.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue growth | +53.4% | -60.8% | +1749.8% | -54.4% | -96.3% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.